Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
NCT ID: NCT01520324
Last Updated: 2019-02-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
53 participants
INTERVENTIONAL
2012-01-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy
NCT01520337
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
NCT02295774
Chromoscopic Guided Endomicroscpy to Diagnose Colitis Associated Dysplasia
NCT00352404
A Phase I In-Vivo Peptide Applied in the Right Colon
NCT01722058
Diagnosis of Rectal Cancer by Electromagnetic Device
NCT00963794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with UC undergoing colonoscopy
oral delivery mucosal stain
200mg methylene blue MMX tablet taken prior to colonoscopy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oral delivery mucosal stain
200mg methylene blue MMX tablet taken prior to colonoscopy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cosmo Technologies Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Silvio Danese, MD
Role: PRINCIPAL_INVESTIGATOR
Humanitas Hospital, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Research & Care of Intestinal Diseases
Rozzano, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CB-17-01/04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.